127 related articles for article (PubMed ID: 6893550)
1. Effect of KC-9432, a new hypolipidemic compound, on high density lipoprotein cholesterol in rats.
Seri K; Sato R; Hamazaki Y; Yamamoto T; Ishiyama N
Atherosclerosis; 1980 Sep; 37(1):97-102. PubMed ID: 6893550
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of BR-931, a new hypolipidemic agent that increases high-density lipoproteins.
Sirtori CR; Gomarasca P; D'Atri G; Cerutti S; Tronconi G; Scolastico C
Atherosclerosis; 1978 May; 30(1):45-56. PubMed ID: 209796
[TBL] [Abstract][Full Text] [Related]
3. [Hypolipidemic activity of substances structurally close to penphenone in rats and mice].
Polikarpova LI; Reznik SE; Ryzhenkov VV; Khechinashvili GG; Petrova LA
Vopr Med Khim; 1978; 24(6):835-9. PubMed ID: 216145
[TBL] [Abstract][Full Text] [Related]
4. Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: I. Chow-fed animals.
O'Brien M; Patel ST; Mukhopadhyay A; Newman HA; Feller DR; Kokrady SS; Witiak DT; Lanese RR; Rice JC
Lipids; 1981 Dec; 16(12):903-11. PubMed ID: 7329211
[TBL] [Abstract][Full Text] [Related]
5. Aminophenyl ether compound (YM-95831), a new hypolipidemic agent with a high density lipoprotein elevating activity in rats.
Ohata I; Sakamoto N; Nitatori R; Maeno H
Arzneimittelforschung; 1983; 33(2):237-41. PubMed ID: 6682662
[TBL] [Abstract][Full Text] [Related]
6. Studies on hypoxic dyslipidaemia. Effect of lipid modulating drugs.
Mälkönen M; Muona M; Manninen V
Acta Med Scand Suppl; 1982; 668():130-5. PubMed ID: 6963088
[TBL] [Abstract][Full Text] [Related]
7. One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson AG; Lang PD
Atherosclerosis; 1978 Dec; 31(4):429-33. PubMed ID: 215175
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the hypolipidemic activity of xenalipin in experimental animals.
Lewis MC; Hodgson GL; Shumaker TK; Namm DH
Atherosclerosis; 1987 Mar; 64(1):27-35. PubMed ID: 3689493
[TBL] [Abstract][Full Text] [Related]
9. Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia.
Olsson AG; Lang PD
Atherosclerosis; 1978 Dec; 31(4):421-8. PubMed ID: 215174
[TBL] [Abstract][Full Text] [Related]
10. Alterations in rat serum lipids and apolipoproteins following clofibrate treatment.
Dashti N; Ontko JA
Atherosclerosis; 1983 Dec; 49(3):255-66. PubMed ID: 6419747
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of benzodioxane, chroman and dihydrobenzofuran analogs of clofibrate in a Triton hyperlipemic rat model.
Newman HA; Heilman WP; Witiak DT
Lipids; 1973 Jul; 8(7):378-84. PubMed ID: 4724016
[No Abstract] [Full Text] [Related]
12. The hypocholesterolemic effect of terbufibrol and other drugs in normal and hypercholesterolemic baboons.
Howard AN; Zschocke R; Löser R; Hofrichter G
Atherosclerosis; 1979 Apr; 32(4):367-80. PubMed ID: 223594
[No Abstract] [Full Text] [Related]
13. The effect of niceritrol (pentaerythritoltetranicotinate) and clofibrate upon hyperlipemia and atherosclerosis induced in rabbits by cholesterol-free semisynthetic diets.
Brattsand R
Atherosclerosis; 1974; 20(3):453-67. PubMed ID: 4373017
[No Abstract] [Full Text] [Related]
14. Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition.
Föger B; Tröbinger G; Ritsch A; Lechleitner M; Hopferwieser T; Menzel HJ; Utermann G; Pfeiffer KP; Patsch JR
Atherosclerosis; 1995 Oct; 117(2):253-61. PubMed ID: 8801871
[TBL] [Abstract][Full Text] [Related]
15. Low density lipoprotein-lowering and high density lipoprotein-elevating effects of nicardipine in rats.
Ohata I; Sakamoto N; Nagano K; Maeno H
Biochem Pharmacol; 1984 Jul; 33(14):2199-205. PubMed ID: 6466343
[TBL] [Abstract][Full Text] [Related]
16. Hypolipidemic potential of perillaldehyde-loaded self-nanoemulsifying delivery system in high-fat diet induced hyperlipidemic mice: Formulation, in vitro and in vivo evaluation.
Omari-Siaw E; Zhu Y; Wang H; Peng W; Firempong CK; Wang YW; Cao X; Deng W; Yu J; Xu X
Eur J Pharm Sci; 2016 Mar; 85():112-22. PubMed ID: 26851382
[TBL] [Abstract][Full Text] [Related]
17. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
Kesäniemi YA; Grundy SM
JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
[TBL] [Abstract][Full Text] [Related]
18. Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
Sircar I; Hoefle M; Maxwell RE
J Med Chem; 1983 Jul; 26(7):1020-7. PubMed ID: 6864730
[TBL] [Abstract][Full Text] [Related]
19. A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients.
Dujovne CA; Azarnoff DL; Pentikainen P; Manion CV; Hurwitz A
Am J Med Sci; 1979; 277(3):255-61. PubMed ID: 222145
[TBL] [Abstract][Full Text] [Related]
20. Serum HDL-cholesterol-increasing and fatty liver-improving actions of Panax ginseng in high cholesterol diet-fed rats with clinical effect on hyperlipidemia in man.
Yamamoto M; Uemura T; Nakama S; Uemiya M; Kumagai A
Am J Chin Med; 1983; 11(1-4):96-101. PubMed ID: 6660221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
